{"id":558860,"date":"2021-08-20T21:28:01","date_gmt":"2021-08-20T21:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=558860"},"modified":"2021-08-20T21:28:01","modified_gmt":"2021-08-20T21:28:01","slug":"idiopathic-pulmonary-fibrosis-treatment-market-epidemiology-emerging-therapies-and-key-companies-working-in-the-domain-during-the-study-period-201730-in-the-7mm","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/idiopathic-pulmonary-fibrosis-treatment-market-epidemiology-emerging-therapies-and-key-companies-working-in-the-domain-during-the-study-period-201730-in-the-7mm_558860.html","title":{"rendered":"Idiopathic Pulmonary Fibrosis Treatment Market, Epidemiology, Emerging Therapies and Key Companies Working in the Domain During the Study Period (2017-30) in the 7MM"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1629455481.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Idiopathic Pulmonary Fibrosis Treatment Market, Epidemiology, Emerging Therapies and Key Companies Working in the Domain During the Study Period (2017-30) in the 7MM\" src=\"https:\/\/www.abnewswire.com\/uploads\/1629455481.png\" alt=\"Idiopathic Pulmonary Fibrosis Treatment Market, Epidemiology, Emerging Therapies and Key Companies Working in the Domain During the Study Period (2017-30) in the 7MM\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Idiopathic Pulmonary Fibrosis Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Idiopathic Pulmonary Fibrosis market size is anticipated to increase due to the launch of the upcoming therapies such as Pamrevlumab, RG6354, Ziritaxestat, and others during the forecast period (2020-30).<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/99ec77d9baac9fd521ccc4a3b8f2f5da.jpg\" alt=\"\" \/><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight&rsquo;s <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Idiopathic Pulmonary Fibrosis market report<\/a><\/strong><span> offers comprehensive coverage of the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Idiopathic Pulmonary Fibrosis (IPF) from 2017 to 2030 segmented into 7MM <\/span><span>(<\/span><span>the United States, EU5 (Germany, Spain, Italy, France, and the UK), and Japan).<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the Key Highlights from the Idiopathic Pulmonary Fibrosis Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>According to DelveInsight&rsquo;s, Idiopathic Pulmonary Fibrosis epidemiology insights, the total prevalent population was estimated to be <\/span><strong>230,123<\/strong><span> in the 7MM in 2020.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>The <\/span><strong>United States<\/strong><span> accounted for the highest Idiopathic Pulmonary Fibrosis prevalent population among the 7MM in 2020. Out of which the highest IPF cases were reported in the <\/span><span><strong>males<\/strong> <\/span><span>as compared to the <\/span><strong>females<\/strong><span>.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Among the EU5 countries, the <\/span><span><strong>UK<\/strong> <\/span><span>has the highest IPF population while <\/span><span><strong>France<\/strong> <\/span><span>had the lowest in 2020.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Some of the major players in the global Idiopathic Pulmonary Fibrosis treatment market in the late phase of clinical development are <\/span><strong>FibroGen, Roche, Galapagos NV, MediciNova, Galecto Biotech, <\/strong><span>and others.&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Key pipeline therapies in the Idiopathic Pulmonary Fibrosis market include <\/span><strong>Pamrevlumab, RG6354, Ziritaxestat, Tipelukast, GB 0139, <\/strong><span>and several others that are anticipated to enter the IPF market in the upcoming years.&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>FibroGen<\/strong><span> is developing <\/span><strong>Pamrevlumab (also known as FG-3019)<\/strong><span><strong>,<\/strong> a first-in-class, a completely humanized monoclonal antibody that suppresses the function of connective tissue growth factor (CTGF), a key mediator in the advancement of fibrosis and other related disorders. It is also being researched for pancreatic cancer and Duchenne muscular dystrophy (DMD) in Phase II developmental stage.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>RG6354 (PRM-151)<\/strong><span> which is being developed by <\/span><span><strong>Roche<\/strong> <\/span><span>is a recombinant human serum amyloid P\/pentraxin 2 protein (PTX2) that is administered intravenously.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Request for a sample to get complete detail on the disease causes, diagnosis, and treatment @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/idiopathic-pulmonary-fibrosis-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Treatment for Idiopathic Pulmonary Fibrosis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Idiopathic Pulmonary Fibrosis market report<\/strong><span> also covers current treatment practices\/algorithms, Idiopathic Pulmonary Fibrosis market drivers, Idiopathic Pulmonary Fibrosis market barriers, and unmet medical needs in order to curate the best opportunities and assess the market&#8217;s underlying potential.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Idiopathic Pulmonary Fibrosis (IPF) is one of the most severe forms of interstitial pneumonia, characterized by chronic, progressive fibrosis, an inexorable decline in lung function, progressive respiratory failure, and a high mortality rate. The disorder&#8217;s classic symptoms include progressive dyspnea and a nonproductive cough. Typically, pulmonary function tests reveal restrictive impairment and decreased carbon monoxide diffusing capacity.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The <\/span><span>Idiopathic Pulmonary Fibrosis<\/span><span> report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Idiopathic Pulmonary Fibrosis Total Diagnosed Prevalent Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Idiopathic Pulmonary Fibrosis Gender-Specific Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Idiopathic Pulmonary Fibrosis Age-Specific Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Idiopathic Pulmonary Fibrosis Prevalent Population by Severity<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Treatment Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Non-pharmacological treatment modalities for Idiopathic Pulmonary Fibrosis include <\/span><span>supplemental oxygen therapy, pulmonary rehabilitation, mechanical ventilation, and palliative care services. <\/span><span>While the pharmacological treatment options for Idiopathic Pulmonary Fibrosis include <\/span><span>Corticosteroids, immunosuppressive\/cytotoxic agents (azathioprine, cyclophosphamide), and antifibrotic agents (e.g., colchicine or d-penicillamine)<\/span><span> can be used alone or in combination. There are two antifibrotic agents that have been approved for Idiopathic Pulmonary Fibrosis treatment namely <\/span><span>Esbriet and Ofev<\/span><span> (tyrosine kinase inhibitors).<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Market<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>The Idiopathic Pulmonary Fibrosis market size was found to be <\/span><strong>USD 2781.75 million<\/strong><span> in the 7MM in 2017.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>The United States accounted for <\/span><strong>79.2% <\/strong><span>of the overall IPF market size among the 7MM in 2017.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Among the EU countries, the <\/span><span><strong>UK<\/strong> <\/span><span>accounted for the highest IPF market share while <\/span><span><strong>France<\/strong> <\/span><span>had the lowest IPF market share.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>The Idiopathic Pulmonary Fibrosis market size is anticipated to increase due to the launch of the upcoming therapies such as <\/span><strong>Pamrevlumab, RG6354, Ziritaxestat, <\/strong><span>and others during the forecast period (2020-30).<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get the detailed analysis of the upcoming therapies @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Idiopathic Pulmonary Fibrosis Drug Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><strong>Idiopathic Pulmonary Fibrosis Pipeline Therapies and Key Companies<\/strong>&nbsp;<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Pamrevlumab: FibroGen<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>RG6354: Roche<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Ziritaxestat: Galapagos NV<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Tipelukast: MediciNova<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>GB 0139: Galecto Biotech<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Management of Comorbidities<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Regulatory designations<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Increase in the Geriatric population<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Increased potential IPF therapies in the pipeline<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Unavailability of IPF cure<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Poor IPF prognosis<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Wait and Watch approach<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope for the Report<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Coverage: <\/strong><span>7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Study Period: <\/strong><span>2017-30<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Key Companies: <\/strong><span>FibroGen, Roche, Galapagos NV, MediciNova, Galecto Biotech<\/span><span>,<\/span><span> among others.<\/span><span>&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Key Pipeline Therapies: <\/strong><span>Pamrevlumab, RG6354, Ziritaxestat, Tipelukast, GB 0139<\/span><span>,<\/span><span>and others.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Segmentation: <\/strong><span>By Geography, By Idiopathic Pulmonary Fibrosis therapies<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis: <\/strong><span>Comparative and conjoint analysis of <\/span><span>Idiopathic Pulmonary Fibrosis <\/span><span>emerging therapies<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Tools Used: <\/strong><span>SWOT Analysis<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Case Studies<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>KOL&rsquo;s Views<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analyst&rsquo;s Views<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"81\" \/>\n<col width=\"543\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><span>1.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Key Insights<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>2.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Executive summary<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>3.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Organizations<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>4.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Idiopathic Pulmonary Fibrosis (IPF): Market Overview at a Glance<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>5.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Idiopathic Pulmonary Fibrosis (IPF): Overview at a Glance<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>6.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>7.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Idiopathic Pulmonary Fibrosis Current Treatment Practices<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>8.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Idiopathic Pulmonary Fibrosis Unmet Needs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>9.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Idiopathic Pulmonary Fibrosis Marketed Drugs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>10.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Idiopathic Pulmonary Fibrosis Emerging Therapies<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>11.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Idiopathic Pulmonary Fibrosis (IPF): 7 Major Market Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>12.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Idiopathic Pulmonary Fibrosis Seven Major Market Outlook<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>13.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Idiopathic Pulmonary Fibrosis United States Market Size<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>14.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Idiopathic Pulmonary Fibrosis Market Drivers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>15.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Idiopathic Pulmonary Fibrosis Market Barriers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>16.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>SWOT Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>17.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Idiopathic Pulmonary Fibrosis Market Access<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>18.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Case Study<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>19.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>KOL&rsquo;s Views<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>20.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>21.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>DelveInsight Capabilities<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>22.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Disclaimer<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>23.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>About DelveInsight<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>For rich insights into Healthcare and Pharmaceutical News, visit <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare, and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/interstitial-lung-disease-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Interstitial Lung Disease Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get a comprehensive analysis of <\/span><span>Interstitial Lung Disease pipeline therapies and <\/span><span>key companies such as <\/span><strong>Roche, OncoArendi Pharmaceuticals, aTyr Pharma, Bristol Myers Squibb<\/strong><span><strong>,<\/strong>&nbsp;<\/span><span>among others.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=idiopathic-pulmonary-fibrosis-treatment-market-epidemiology-emerging-therapies-and-key-companies-working-in-the-domain-during-the-study-period-201730-in-the-7mm\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=idiopathic-pulmonary-fibrosis-treatment-market-epidemiology-emerging-therapies-and-key-companies-working-in-the-domain-during-the-study-period-201730-in-the-7mm\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Idiopathic Pulmonary Fibrosis Market The Idiopathic Pulmonary Fibrosis market size is anticipated to increase due to the launch of the upcoming therapies such as Pamrevlumab, RG6354, Ziritaxestat, and others during the forecast period (2020-30). DelveInsight&rsquo;s Idiopathic Pulmonary Fibrosis market report &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/idiopathic-pulmonary-fibrosis-treatment-market-epidemiology-emerging-therapies-and-key-companies-working-in-the-domain-during-the-study-period-201730-in-the-7mm_558860.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-558860","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/558860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=558860"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/558860\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=558860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=558860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=558860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}